Last updated: August 1, 2025
Introduction
ISOVUE-128, a contrast agent used in medical imaging, specifically for computed tomography (CT) scans, is marketed by Bracco Diagnostics Inc. It is a proprietary iodine-based contrast media designed to enhance the visibility of vascular structures and organs during diagnostic procedures. Due to its specialized application and regulatory exclusivity, sourcing ISOVUE-128 involves understanding its manufacturing landscape, authorized suppliers, and global distribution channels.
Overview of ISOVUE-128
ISOVUE-128 contains the active pharmaceutical ingredient (API) iopamidol at a concentration of 370 mg/mL, encapsulated within a sterile, aqueous solution. Its primary indications are for imaging of the central nervous system, vascular structures, and abdominal organs. As a contrast media, its supply chain is tightly controlled due to safety considerations, regulatory compliance, and the limited number of authorized manufacturers.
Manufacturers of ISOVUE-128
The drug is developed and supplied by Bracco Diagnostics Inc., a subsidiary of Bracco S.p.A. headquartered in Italy, which has a significant market presence in the global radiology and contrast media space. Bracco operates multiple manufacturing facilities worldwide, especially in Italy, the United States, and various European locations, adhering to strict Good Manufacturing Practices (GMP).
Authorized Suppliers and Distribution Channels
1. Direct Supply from Bracco
As the principal manufacturer, Bracco Supplies ISOVUE-128 directly to hospitals, clinics, and radiology centers through its extensive distribution network. The company maintains a supply chain that is tightly regulated to ensure product integrity and compliance with health authorities such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency).
2. Authorized Distributors
Bracco partners with regional and national pharmaceutical distributors to ensure broad availability. These authorized distributors are approved through strict quality assurance protocols and are the primary points for bulk procurement, especially among hospital networks and government procurement systems:
- McKesson Corporation
- Cardinal Health
- Henry Schein Medical
- Medline Industries
Access to ISOVUE-128 via these distributors requires adherence to legal and regulatory frameworks, including proper licensing and handling protocols.
3. Regional Suppliers and Importers
In emerging markets and countries with local pharmaceutical regulations, authorized importers and regional distributors procure ISOVUE-128 directly from Bracco or its authorized agents. These entities often serve as intermediaries, ensuring availability while maintaining compliance with local regulatory requirements.
Regulatory Considerations in Supplier Selection
Regulatory approval is critical in sourcing ISOVUE-128. The drug is approved by the FDA under the brand name ISOVUE-128, with similar approvals in Europe, Asia, and other regions. Any supplier or distributor must hold requisite licenses and certifications to handle and distribute radiological contrast agents.
Pharmaceutical supply chains are monitored for counterfeit products. Therefore, purchase only from authorized suppliers verified by regulatory agencies and the manufacturer. This strategy minimizes safety risks and regulatory violations.
Supply Chain Challenges and Risks
The global supply chain for contrast agents like ISOVUE-128 faces challenges such as:
- Regional regulatory restrictions
- Manufacturing delays due to quality control issues
- Demand fluctuation, especially during global health crises
- Limited number of authorized manufacturers, creating dependency on few suppliers
These factors can impact availability and pricing, emphasizing the importance of establishing reliable supplier relationships.
Emerging Alternatives and Supply Diversification
While Bracco remains the primary supplier of ISOVUE-128, healthcare providers increasingly explore alternative contrast agents such as Iohexol (Omnipaque) and Visipaque (iodixanol) to diversify supply sources, especially during shortages. However, switching agents requires clinicians to consider compatibility, efficacy, and safety profiles.
Future Outlook
Continued regulatory scrutiny and technological advances may lead to new manufacturers entering the contrast media market, potentially expanding supply options for ISOVUE-128. Additionally, biosimilar development could impact pricing and accessibility.
Conclusion
Sourcing ISOVUE-128 necessitates navigating a tightly controlled supply chain dominated by Bracco and its authorized distributors. Ensuring product authenticity, regulatory compliance, and supply stability are critical for healthcare providers. Strategic relationships with verified suppliers and proactive supply chain management are essential to mitigate risks and maintain continuous access to this vital contrast agent.
Key Takeaways
- Primary Manufacturer: Bracco Diagnostics Inc., with manufacturing facilities in Italy and the U.S.
- Authorized Distribution: Through regional and national distributors like McKesson and Cardinal Health
- Regulatory Compliance: Suppliers must be licensed and compliant with FDA, EMA, and local health authority regulations
- Supply Risks: Limited manufacturers, demand fluctuations, and regional restrictions pose challenges
- Supply Chain Strategy: Engage only with verified, authorized suppliers to safeguard authenticity and availability
FAQs
1. Is ISOVUE-128 available from multiple suppliers globally?
Primarily, ISOVUE-128 is supplied directly by Bracco and its authorized distributors globally. Availability may vary by region due to regulatory restrictions and local distribution agreements, but the product remains concentrated within a few authorized suppliers to assure safety and compliance.
2. How can healthcare providers ensure the authenticity of ISOVUE-128?
Procure exclusively through verified, authorized distributors certified by Bracco or governed by regulatory agencies such as the FDA or EMA. Cross-verification of supplier credentials and adherence to procurement regulations are essential.
3. Are there regional variations in ISOVUE-128 supply?
Yes. While Europe, North America, and Asia primarily receive supplies directly from Bracco or authorized partners, emerging markets may rely on licensed importers, which could influence availability and pricing.
4. What are the risks associated with sourcing from non-authorized suppliers?
Risks include product counterfeit, substandard quality, regulatory non-compliance, and potential safety hazards. Such risks can lead to adverse patient outcomes and legal liabilities.
5. Are there alternative contrast agents to ISOVUE-128?
Yes. Alternatives like Iohexol (Omnipaque) and iodixanol (Visipaque) are used in similar applications. However, switching agents must involve clinician consultation to ensure compatibility and efficacy, and these alternatives may have different supply chains.
Sources
- Bracco Diagnostics Inc. Official product information and supply chain disclosures.
- U.S. Food and Drug Administration (FDA). Drug Approval Records for ISOVUE-128.
- European Medicines Agency (EMA). Summary of product characteristics for iodine-based contrast media.
- Industry reports on contrast media manufacturing and distribution.
- Regulatory guidelines on pharmaceutical supply chain integrity.
